drugset / Trial / NCT04321993
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Phase 2
Unknown
363 enrolled
Lisa Barrett
Dalhousie University · collabNova Scotia Health Authority · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons with moderate to severe COVID-19 disease that meet eligibility criteria will be offered participation.
Timeline
- Start
- 2020-04-17
- Primary completion
- 2024-04
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Subject | Remdesivir | Small molecule | 100 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |